What is the outlook for the biosimilar market in the next decade?

Globally, the use of biosimilars is growing rapidly and will continue to rise over the next decade
.

According to IQVIA Forecast Link statistics, from 2015 to 2020, the biosimilar market continued to grow at a compound annual growth rate of 7.

Globally, the use of biosimilars is growing rapidly and will continue to rise over the next decade

Future Trends Key Drivers of Usage Differences Between Different Regions and Product Types

In recent years, the sales share of biosimilars launched in different regions and different molecules has different trends
.

Globally, trends in the use of insulin analogs used to treat diabetes, such as insulin glargine and insulin lispro, have been flat, while bevacizumab, rituximab, and The use of biosimilars such as trastuzumab in oncology is rapidly increasing

In recent years, the sales share of biosimilars launched in different regions and different molecules has different trends

However, there are exceptionsat the national level , mainly due to the acceptance of doctors and patients , policy incentives, price differences , and whether the country adopts a unilateral or multi-party bidding system
.

As far as insulin is concerned, due to safety and efficacy considerations, doctors and patients are not willing to

Countries with exception acceptance, policy incentives, and price differences are not willing to adopt a unilateral or multi-party bidding system

The key driver for the development of the biosimilar market in the next decade will be the number of original products whose patents have expired during the same period
.

Product patent expiry is a forecast hypothetical event considered by IQVIA Forecast Link, and its timing is mainly determined by the expiry of key patents, but also takes into account the evidence of the research and development progress of biosimilars under investigation

The number of original research products whose patents expired in the same period

The IQVIA Forecast Link reviews the historical use of biosimilars at the country level and provides an outlook on future use of biosimilars (by tumor, insulin and other molecules) based on historical trends and expert forecasts .
If comparable historical data is not available for the country, IQVIA Forecast Link uses regional averages as a reference .
The above data will be used to predict the change in the sales share between the original biological product and its biosimilar whose patents have expired in the future .
The forecast trend based on data adjustments for the second quarter of 2021 is shown in the chart below .

Historical trends and expert forecast usage regional averages

At a regional level, Europe and North America are expected to remain the same in 2030, despite a higher CAGR of biosimilar usage (measured in PATDAY) in key Asian markets, Latin America and Southeast Asia, and Australasia over the next decade.

will occupy the majority of the market share of the biosimilar market

Although the use of biosimilars varies widely by molecule and region , it is certain that the market size of biosimilars will grow substantially over the next decade .

In the future, the expiry of a large number of drug patents and a larger reduction in medical expenses will be important factors driving the continued growth of the biosimilar market .

Molecular and regional differences